Broadening its cell therapy pipeline, GlaxoSmithKline has agreed to partner with Immatics Biotechnologies to develop T-cell receptor therapies for the treatment of cancer. While the main focus of the deal with be on autologous T-cell therapies, the parties will have an option to also explore allogeneic cell therapies using Immatics’ ACTallo® approach that can be used to create “off-the-shelf” products. The deal comes six months after Immatics’ signed a US$1.6 B deal with Celgene to also explore adoptive cell therapies.